# Combined α + β Blockers

## Examples

- `labetalol`
- `carvedilol`

> These drugs block both β-adrenergic and α₁-adrenergic receptors — leading to reduced cardiac output **and** peripheral resistance.

## Mechanism of Action (MOA)

- **β₁-blockade:** ↓ heart rate, ↓ myocardial contractility, ↓ renin release.
- **β₂-blockade:** ↓ sympathetic-mediated vasodilation (minor role).
- **α₁-blockade:** Vasodilation → ↓ total peripheral resistance → ↓ afterload.
  → **Net effect:** Reduction in BP without significant reflex tachycardia or fall in cardiac output.

## Pharmacodynamics

- Balanced decrease in **cardiac output** and **systemic vascular resistance**.
- **No major reflex tachycardia** due to β-blockade counteracting α₁-induced vasodilation.
- **Antioxidant** (notably `carvedilol`): scavenges reactive oxygen species and prevents lipid peroxidation — beneficial in heart failure.
- Improves **left ventricular function** and reduces **mortality** in chronic heart failure.

## Pharmacokinetics

| Drug         | Route    | Half-life | Remarks                                                                                                        |
| ------------ | -------- | --------- | -------------------------------------------------------------------------------------------------------------- |
| `labetalol`  | Oral, IV | 6–8 h     | Extensive first-pass metabolism[^1]; IV form used in hypertensive emergencies & pregnancy-induced hypertension |
| `carvedilol` | Oral     | 7–10 h    | Highly lipophilic; hepatic metabolism (CYP2D6, CYP2C9); long duration; used in CHF                             |

[^1]: **First-pass metabolism**: The degree of metabolic breakdown of an orally administered drug that occurs in the intestine or liver before it reaches the systemic circulation. It is also known as the first-pass effect and results in a reduction in the concentration of the drug

## Indications

- **Hypertension** (especially in pregnancy — `labetalol`)
- **Hypertensive emergencies** (IV `labetalol`)
- **Chronic heart failure** (`carvedilol`)
- **Ischemic heart disease**
- **Pheochromocytoma (adjuvant)** — with α-blockade first

## Adverse Effects

- Postural hypotension (α₁-blockade)
- Dizziness, fatigue
- Bradycardia, heart block
- Cold extremities
- Bronchospasm (β₂-blockade)
- Hepatic dysfunction (rare with `labetalol`)

## Cautions

- Asthma or COPD (due to β₂-blockade)
- Diabetes mellitus (may mask hypoglycemia)
- Hepatic impairment (requires dose adjustment)
- Avoid abrupt withdrawal

## Contraindications

- **Severe bradycardia or heart block**
- **Cardiogenic shock or acute heart failure**
- **Asthma** (relative)
- **Severe hepatic impairment**
